Vimeo is coming off a big year of changes in 2017. From abandoning SVOD, to launching Vimeo Live, 360-degree video, and its first camera. The company's CEO Anjali Sud explains how these changes are driving growth for the company.
New York Governor Andrew Cuomo recently proposed government funding for a study to explore the impact of legalizing recreational marijuana in the state. State Senator Gustavo Rivera (D-NY) and High NY Founder and CEO Michael Zaystev discuss the state of regulation in New York.
This weekend the New York Times released an investigative piece on the dark world of buying followers and bots for social media fame and recognition. Since the report has been released, the fallout has been significant. Nicholas Confessore, reporter at the New York Times, joins Cheddar to talk about his report and what the reaction has been.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
ReturnPro CEO Sender Shamiss to discuss how his company is changing the way we make returns and how Trump's tariffs are affecting the return business. Watch!
Chris Beauchamp, Chief Market Analyst at IG International, joins J.D. Durkin to give analysis on the recent trade truce between the U.S. and China. Watch!
Shan Aggarwal, VP of Corporate and Business Development at Coinbase, discusses the company's acquisitio of Deribit as it heads into the S&P 500. Watch!
Shopping expert Trae Bodge discusses how talks between the U.S. and China is good news for now, but uncertainty remains for back-to-school and the holidays.
Jake Traylor, White House reporter at Politico, joins Cheddar to discuss how Trump is aiming to lower drug prices and how it differs from Biden's approach.
